FR3048884B1 - Composition pour l'administration par voie orale d'au moins un principe actif a un sujet - Google Patents

Composition pour l'administration par voie orale d'au moins un principe actif a un sujet Download PDF

Info

Publication number
FR3048884B1
FR3048884B1 FR1652329A FR1652329A FR3048884B1 FR 3048884 B1 FR3048884 B1 FR 3048884B1 FR 1652329 A FR1652329 A FR 1652329A FR 1652329 A FR1652329 A FR 1652329A FR 3048884 B1 FR3048884 B1 FR 3048884B1
Authority
FR
France
Prior art keywords
composition
subject
oral administration
active substance
active principle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1652329A
Other languages
English (en)
Other versions
FR3048884A1 (fr
Inventor
Victor Roullier
Arnaud Picot
Anthony Gourdon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capsulae Fr
Original Assignee
Capsulae SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capsulae SAS filed Critical Capsulae SAS
Priority to FR1652329A priority Critical patent/FR3048884B1/fr
Publication of FR3048884A1 publication Critical patent/FR3048884A1/fr
Application granted granted Critical
Publication of FR3048884B1 publication Critical patent/FR3048884B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pour l'administration par voie orale d'au moins un principe actif à un sujet. Cette composition comprend des particules d'hydrogel, avantageusement sous forme humide ou sèche, comprenant : - ledit au moins un principe actif, - au moins un polysaccharide gélifiant, - au moins un agent de charge, et - au moins un agent protecteur, choisi parmi les protéines et/ou les résines alimentaires, aptes à conférer une protection dudit au moins un principe actif dans un milieu dont le pH est inférieur à 5,5, lesquelles particules sont aptes à libérer au moins une partie dudit au moins un principe actif dans un milieu dont le pH est supérieur à 5,5.
FR1652329A 2016-03-18 2016-03-18 Composition pour l'administration par voie orale d'au moins un principe actif a un sujet Active FR3048884B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1652329A FR3048884B1 (fr) 2016-03-18 2016-03-18 Composition pour l'administration par voie orale d'au moins un principe actif a un sujet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1652329A FR3048884B1 (fr) 2016-03-18 2016-03-18 Composition pour l'administration par voie orale d'au moins un principe actif a un sujet

Publications (2)

Publication Number Publication Date
FR3048884A1 FR3048884A1 (fr) 2017-09-22
FR3048884B1 true FR3048884B1 (fr) 2021-07-30

Family

ID=56555469

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1652329A Active FR3048884B1 (fr) 2016-03-18 2016-03-18 Composition pour l'administration par voie orale d'au moins un principe actif a un sujet

Country Status (1)

Country Link
FR (1) FR3048884B1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226905A1 (en) * 2001-05-22 2005-10-13 Tien Canh L Biocompatible compositions as carriers or excipients for pharmaceutical and nutraceutical formulations and for food protection
ITMI20031617A1 (it) * 2003-08-06 2005-02-07 Fond Carlo E Dirce Callerio Onlus Microcapsule a doppio strato di polisaccaridi utilizzabili
US9089152B2 (en) * 2009-04-13 2015-07-28 TEAGASC—Agriculture and Food Development Authority Method of producing microbeads
CN101856604A (zh) * 2010-06-04 2010-10-13 上海理工大学 一种用静电喷雾制备益生菌微胶囊的方法
US9788563B2 (en) * 2011-04-15 2017-10-17 Pepsico, Inc. Encapsulation system for protection of probiotics during processing
CN103110153A (zh) * 2013-02-05 2013-05-22 浙江大学 一种果蔬复合颗粒饮料及其制备方法
CN104911171A (zh) * 2015-05-25 2015-09-16 淮阴工学院 以海藻酸钠、明胶复合凹土制备益生菌微胶囊的方法

Also Published As

Publication number Publication date
FR3048884A1 (fr) 2017-09-22

Similar Documents

Publication Publication Date Title
EP4374851A3 (fr) Composition ophtalmique pour le traitement d'une maladie de l' il sec
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
EP4292650A3 (fr) Composés hétérocycliques en tant qu'immunomodulateurs
WO2007027941A3 (fr) Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue
MX2019010598A (es) Composicion farmaceutica que comprende selexipag.
TR200801336T1 (tr) Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
WO2007019232A3 (fr) Formulations d'immunoconjugué
BR112012016021A2 (pt) formulações estáveis para liofilização de partículas terapêuticas
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
WO2007053197A3 (fr) Preparations nanoparticulaires a base d'acetaminophene
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA31927B1 (fr) Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
BR112018074311A2 (pt) composição líquida, e, uso de composição líquida.
AU2019339740A8 (en) CSF-1R antibody formulation
WO2007058862A3 (fr) Composes d’imidazolidinone utiles en tant qu’inhibiteurs de la beta-secretase lors du traitement de la maladie d’alzheimer
FR3056909B1 (fr) Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
FR3048177B1 (fr) Composition cosmetique biphase et son utilisation par application topique
WO2007075572A3 (fr) Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90
MX2017010666A (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
FR3048884B1 (fr) Composition pour l'administration par voie orale d'au moins un principe actif a un sujet
HK1120417A1 (en) Stable nanoparticle formulations
EP4327871A3 (fr) Compositions pharmaceutiques à libération modifiée d'huperzine et leurs procédés d'utilisation
FR3042409B1 (fr) Emulsion comprenant une charge a effet flouteur et un pigment composite a base d'alumine plaquettaire, d'oxyde metallique et d'un agent de traitement de surface
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170922

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

TP Transmission of property

Owner name: CAPSULAE, FR

Effective date: 20240311